Clinical Trial: Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor

Brief Summary:

This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma.

Background: Cabergoline is a Dopamine 2 receptor agonist. Corticotroph adenoma has shown to have the D2 receptor in in vitro studies.

Detailed Summary:
Sponsor: Seth Gordhandas Sunderdas Medical College

Current Primary Outcome: Response in term of mid night cortisol < 5.0 mcg/dl and/or Standard two day dexamethasone suppression test < 1.8 mcg/dl

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Seth Gordhandas Sunderdas Medical College

Dates:
Date Received: April 27, 2009
Date Started: November 2007
Date Completion:
Last Updated: April 28, 2009
Last Verified: April 2009